Nitrosoglutathione
Based on 11 publication(s) in Google Scholar
Nitrosoglutathione (GSNO), a exogenous NO donor and a substrate for rat alcohol dehydrogenase class III isoenzyme, inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 90.0%
- CAS No.: 57564-91-7
- Formule: C10H16N4O7S
- Masse moléculaire:336.32
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Human Endogenous Metabolite Compound Library
HY-L030
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Neurotransmitter Receptor Compound Library
HY-L062
-
Angiogenesis-Related Compound Library
HY-L088
-
Food-Sourced Compound Library
HY-L094
-
Pediatric Drug Library
HY-L104
-
Human Metabolite Library
HY-L123
-
Cuproptosis Compound Library
HY-L133
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Animal-Sourced Natural Product Library
HY-L157
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Clinical Compound Library Plus
HY-L026P
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Endogenous Metabolite Library
HY-L207
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Nitrosoglutathione
More- Adv Mater. 2026 Mar 15:e20199. [Abstract]
- Nat Commun. 2026 May 30. [Abstract]
- Nat Commun. 2025 Apr 27;16(1):3953. [Abstract]
- J Nanobiotechnology. 2025 Dec 20. [Abstract]
- Adv Sci (Weinh). 2025 Jun;12(22):e2417208. [Abstract]
- Adv Healthc Mater. 2025 Aug 29:e00457. [Abstract]
- Int J Biol Macromol. 2025 Dec;332(Pt 2):148578. [Abstract]
- Small Sci. 2025 Jun 1;5(8):2500151. [Abstract]
- Plant J. 2025 Jul;123(2):e70379. [Abstract]
- Adv Mater Interfaces. 2026 Apr 5.
- Nitric Oxide. 2025 May 27:158:27-37. [Abstract]
Customer Validation & Images
-
WB
-
IF
-
IP
-
Others
-
Others
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
MoreVoir tous les produits spécifiques à Isoform Angiotensin Receptor
More
Activité biologique
|
AT1 Receptor |
Human Endogenous Metabolite |
Nitrosoglutathione (GSNO, 250 μM) prevents 90% of the response to 0.1 μM 5-HT and 40% of the response to 1.0 μM 5-HT in rings treated with LY-83583, indicating an effect of GSNO that was independent of guanylate cyclase activity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Nitrosoglutathione (GSNO, 0.2 and 0.6 mg/kg) significantly inhibits superoxide production and suppressed NF-κB activation, iNOS induction, and 3-nitrotyrosine expression, but up-regulates endothelial NOS expression in the flap vessels[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Lewis rats[4].
-
Dosage:0.2 and 0.6 mg/kg.
-
Administration:Slow intravenous injection via the opposite femoral vein into each rat.
-
Result:Animals treated with 0.2 mg of GSNO per kilogram before reperfusion had an intermediate survival rate (40.2 ± 4.9%). Although 0.6 mg/kg of GSNO showed a better rescuing effect than 150 mg/kg of NAC, there was no significant difference between the groups.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 57564-91-7
-
Appearance Solid
-
Masse moléculaire 336.32
-
Formule C10H16N4O7S
-
Color Pink to red
-
SMILES
OC(CNC([C@H](CSN=O)NC(CC[C@H](N)C(O)=O)=O)=O)=O
-
Synonyms
GSNO; RVC-588; S-Nitroso-L-glutathione
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Deployable 3D-Printed Vascular Stent with Surface-Catalysed Endogenous Nitric Oxide Generation. [Abstract]2026 Mar 15:e20199. PMID: 41834292 -
Nat Commun
A labile sulfur ligand in a three-cysteine-coordinated [2Fe-2S] cluster mediates sulfide sensing in NreB. [Abstract]2026 May 30. PMID: 42218159 -
Nat Commun
S-nitrosylation of EZH2 alters PRC2 assembly, methyltransferase activity, and EZH2 stability to maintain endothelial homeostasis. [Abstract]2025 Apr 27;16(1):3953. PMID: 40289112
Nitrosoglutathione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 27;16(1):3953. [Abstract]
Immunoblotting for EZH2 and H3K27me3 in cultured EA.hy926 cells exposed to GSNO (Nitrosoglutathione: 100 μM).
Nitrosoglutathione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 27;16(1):3953. [Abstract]
Immunofluorescence followed by confocal imaging of EA.hy926 cells exposed to 1 h of GSNO (Nitrosoglutathione: 100 μM) and labeled for EZH2 (green) and F-actin (red). DAPI staining is shown in blue. White and yellow arrow head indicates EZH2 not bound and bound to F-actin respectively.
Nitrosoglutathione purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 27;16(1):3953. [Abstract]
EA.hy926 cells treated with GSNO (Nitrosoglutathione: 100 μM) for 0.5 h were subjected to co-immunoprecipitation using EZH2 antibody followed by immunoblotting for SUZ12.
-
J Nanobiotechnology
Nitric oxide-releasing nanocarriers integrated with ginsenoside compound K in dissolvable microneedles for androgenetic alopecia. [Abstract]2025 Dec 20. PMID: 41422253 -
Adv Sci (Weinh)
Ultrasound-Responsive 4D Bioscaffold for Synergistic Sonopiezoelectric-Gaseous Osteosarcoma Therapy and Enhanced Bone Regeneration. [Abstract]2025 Jun;12(22):e2417208. PMID: 40178027 -
Adv Healthc Mater
Nitric Oxide-Releasing Catheters with Phenol-Amine Catalytic Coatings for Improved Anti-Inflammatory Performance. [Abstract]2025 Aug 29:e00457. PMID: 40879081 -
Int J Biol Macromol
A magnetic nanoparticles-based ligand fishing method coupled with parallel artificial membrane permeability assay for rapid discovery and analysis of GSNO reductase inhibitors with good membrane permeability from Salvia miltiorrhiza Bunge. [Abstract]2025 Dec;332(Pt 2):148578. PMID: 41176011 -
Small Sci
Polydopamine-Coated Selenium Nanoparticles as a Stable Catalyst for Tunable and Sustained Nitric Oxide Generation. [Abstract]2025 Jun 1;5(8):2500151. PMID: 40837046
Nitrosoglutathione purchased from MedChemExpress. Usage Cited in: Small Sci. 2025 Jun 1;5(8):2500151. [Abstract]
In PBS buffer (pH 5.5, 7.4, and 8.5), the cumulative NO generation of GSNO (Nitrosoglutathione: 50 μM) in the presence or absence of SeNPs (40 μg/mL) over 4 hours was measured.
Nitrosoglutathione purchased from MedChemExpress. Usage Cited in: Small Sci. 2025 Jun 1;5(8):2500151. [Abstract]
In PBS at pH 8.5, using 40 μg/mL SeNPs or Se@PDA NPs as catalysts, the accumulation of NO from GSNO (Nitrosoglutathione: 50 μM) over time was observed.
-
Plant J
Nitric oxide delays floral transition in Arabidopsis by inhibiting histone deacetylases HDA5 and HDA6. [Abstract]2025 Jul;123(2):e70379. PMID: 40726229 -
-
Nitric Oxide
Comprehensive evaluation of S-nitrosoglutathione and S-nitroso-N-acetylpenicillamine stability in biomedical contexts. [Abstract]2025 May 27:158:27-37. PMID: 40441475
Solvant et solubilité
H2O : 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Marie-Lynda Bouressam, et al. S-nitrosoglutathione inhibits cerebrovascular angiotensin II-dependent and -independent AT 1 receptor responses: A possible role of S-nitrosation. Br J Pharmacol. 2019 Jun;176(12):2049-2062. [Content Brief]
[2]. D E Jensen, et al. S-Nitrosoglutathione is a substrate for rat alcohol dehydrogenase class III isoenzyme. Biochem J. 1998 Apr 15;331 ( Pt 2)(Pt 2):659-68. [Content Brief]
[3]. Caneta Brown, et al. The effects of S-nitrosoglutathione and S-nitroso-N-acetyl-D, L-penicillamine in a rat model of pre-eclampsia. J Nat Sci Biol Med. 2013 Jul;4(2):330-5. [Content Brief]
[4]. Yur-Ren Kuo, et al. Nitrosoglutathione promotes flap survival via suppression of reperfusion injury-induced superoxide and inducible nitric oxide synthase induction. J Trauma. 2004 Nov;57(5):1025-31. [Content Brief]
[5]. Eva Nozik-Grayck, et al. Pulmonary vasoconstriction by serotonin is inhibited by S-nitrosoglutathione. Am J Physiol Lung Cell Mol Physiol. 2002 May;282(5):L1057-65. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.9734 mL | 14.8668 mL | 29.7336 mL | 74.3340 mL |
| 5 mM | 0.5947 mL | 2.9734 mL | 5.9467 mL | 14.8668 mL | |
| 10 mM | 0.2973 mL | 1.4867 mL | 2.9734 mL | 7.4334 mL | |
| 15 mM | 0.1982 mL | 0.9911 mL | 1.9822 mL | 4.9556 mL | |
| 20 mM | 0.1487 mL | 0.7433 mL | 1.4867 mL | 3.7167 mL | |
| 25 mM | 0.1189 mL | 0.5947 mL | 1.1893 mL | 2.9734 mL | |
| 30 mM | 0.0991 mL | 0.4956 mL | 0.9911 mL | 2.4778 mL | |
| 40 mM | 0.0743 mL | 0.3717 mL | 0.7433 mL | 1.8583 mL | |
| 50 mM | 0.0595 mL | 0.2973 mL | 0.5947 mL | 1.4867 mL | |
| 60 mM | 0.0496 mL | 0.2478 mL | 0.4956 mL | 1.2389 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Nitrosoglutathione Related Classifications
HY-D0845 Related Classifications
Powered by Bioz